Table 1.
Factor | Study Type (n) |
---|---|
Low baseline FVC | |
Morgan et al., 2003 (15) | Single-center, prospective cohort (561) |
Plastiras et al., 2006 (16) | Single-center, retrospective cohort (78) |
Nihtyanova et al., 2014 (17) | Single-center, prospective cohort (398) |
Steen et al., 1994 (8) | Single-center, retrospective cohort (890) |
Low baseline DlCO | |
Morgan et al., 2003 (15) | Single-center, prospective cohort (561) |
Nihtyanova et al., 2014 (17) | Single-center, prospective cohort (398) |
Extent of ILD on HRCT | |
Goh et al., 2008 (18) | Single-center, prospective cohort (330) |
Moore et al., 2013 (19) | Multicenter, retrospective cohort (172) |
Khanna et al., 2011 (20) | Multicenter, randomized controlled trial (placebo group, 79) |
Anti-topoisomerase I antibodies | |
Assassi et al., 2010 (21) | Single-center, prospective cohort (125) |
Nihtyanova et al., 2014 (17) | Single-center, prospective cohort (398) |
Diffuse cutaneous sclerosis | |
Nihtyanova et al., 2014 (17) | Single-center, prospective cohort (398) |
IL-6 | |
De Lauretis et al., 2013 (22) | Single-center, exploratory (74) and test cohorts (212) |
C-reactive protein (CRP) | |
Liu et al., 2013 (23) | Single-center, prospective cohort (266) |
Monocyte chemoattractant protein-1 (MCP-1) | |
Wu et al., 2013 (24) | Single-center, prospective cohort (266) |
CC chemokine ligand 18 (CCL18) | |
Tiev et al., 2011 (25) | Single-center, prospective cohort (83) |
Schupp et al., 2014 (26) | Single-center, prospective cohort (96) |
CXCL4 | |
van Bon et al., 2014 (27) | Single-center prospective cohort (79) |
Krebs von den Lungen-6 (KL-6) | |
Yanaba et al., 2004 (28) | Single-center, retrospective cohort (42) |
Surfactant protein D (SP-D) | |
Yanaba et al., 2004 (28) | Single-center, retrospective cohort (42) |
Definition of abbreviations: DlCO = diffusing capacity of the lung for carbon monoxide; HRCT = high-resolution computed tomography; ILD = interstitial lung disease.